Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System
Open Forum Infectious Diseases · 2026-11-12
DOI: 10.1093/ofid/ofag706 ↗Abstract
Abstract Background Mycobacterium tuberculosis (MTB) disease is a global health threat with most cases occurring in low-and middle-income countries (LMIC) with limited healthcare infrastructure. Near-point-of-care testing deployed at peripheral clinical settings is needed to start treatment earlier and thereby improve treatment outcomes. Methods We developed a rapid MTB detection assay for the DASH® Rapid PCR System with cartridge-based sample prep and dual target qPCR multicopy MTB insertion sequences IS6110 and IS1081 amplification. The limit of detection and analytical specificity of the RUO (research use only) DASH MTB assay were evaluated. Two clinical evaluations were performed using 110 (70 positive and 40 negative) de-identified blinded tongue swab specimens and 100 (49 positive and 51 negative) de-identified blinded sputum specimens from South African symptomatic clinic attendees. Results The DASH assay demonstrated a limit of detection of 2.5 MTB cells/swab with no detection of 10 non-tuberculosis Mycobacterium strains. The clinical sensitivity of tongue swab specimens was 91% and the specificity was 100% as compared to Xpert Ultra results on paired sputum specimens. The overall clinical sensitivity of sputum specimens was 96% (100% for smear positive and 88% for smear negative samples) and specificity of 88% when compared to sputum culture. The DASH test is compatible with peripheral LMIC settings via external battery operation and cartridge stability at 45°C for one year. Conclusions The DASH MTB’s assay demonstrated high sensitivity and specificity, rapid time to result, and compatibility with environments that lack air conditioning and consistent electricity make this assay suitable for diverse clinical settings.
EUVIMED